Shots:
- Biocon has entered into a partnership agreement with Bahiafarma & Bionovis for pertuzumab biosimilar in Brazil to advance production & commercialisation of the HER2+ breast cancer therapy under the country’s PDP program
- The Biocon, Bahiafarma & Bionovis consortium received 100% allocation under 10-year PDP program for pertuzumab, providing exclusive access to the public healthcare market, and supporting long-term adoption in the public oncology network
- Biocon will receive milestone payments and a share of revenues from the Brazil PDP opportunity over 10 years, with the product undergoing phased localization in Brazil over the mid to long term
Ref: Biocon | Image: Biocon | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
